Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Bristol-Myers Squibb Pharmaceuticals Limited, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH
AMIKIN INJECTION 100MG/2ML.
| Pharmaceutical Form |
|---|
|
Solution for administration to human beings by injection. |
Each vial contains in 2 mL amikacin sulfate equivalent to amikacin activity 100 mg (100,000 international units).
Excipient with known effect: Each vial contains 2.64 mg (0.13 mmol) sodium metabisulfite (E223).
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Amikacin is an antibiotic used for a number of bacterial infections. Amikacin works by blocking the function of the bacteria’s 30S ribosomal subunit, making it unable to produce proteins. |
| List of Excipients |
|---|
|
Sodium metabisulfite (E223) |
Five 2 mL flint glass Type 1 vial with butyl rubber stopper and aluminium seal in a cardboard carton.
Bristol-Myers Squibb Pharmaceuticals Limited, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH
PL 11184/0136
Date of first authorisation: 26th August 1976
Date of latest renewal: 25th November 2005
| Drug | Countries | |
|---|---|---|
| AMIKIN | Hong Kong, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.